Expand FULC Menu
FULC MENU

FULC Latest Press Releases

-- February 24, 2026 --

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025 Globe Newswire 7:01 AM
Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease Globe Newswire 7:00 AM

-- February 17, 2026 --

Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease Globe Newswire 8:00 AM

-- February 6, 2026 --

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- January 9, 2026 --

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- January 7, 2026 --

Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference Globe Newswire 8:00 AM

-- December 10, 2025 --

Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants Globe Newswire 7:48 AM

-- December 8, 2025 --

Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock Globe Newswire 4:01 PM

-- December 6, 2025 --

Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting Globe Newswire 5:30 PM

-- December 5, 2025 --

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- December 2, 2025 --

Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025 Globe Newswire 8:30 AM

-- November 7, 2025 --

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- November 3, 2025 --

Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting Globe Newswire 4:45 PM

-- October 29, 2025 --

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025 Globe Newswire 7:00 AM

-- October 22, 2025 --

Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET Globe Newswire 8:54 AM

-- October 14, 2025 --

Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025 Globe Newswire 7:00 AM

-- October 10, 2025 --

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM
Market Data Delayed 15 Minutes